Matching articles for "glioma"

Tovorafenib (Ojemda) for Pediatric Low-Grade Glioma (online only)

   
The Medical Letter on Drugs and Therapeutics • June 10, 2024;  (Issue 1704)
Tovorafenib (Ojemda – Day One), a type II RAF kinase inhibitor, has received accelerated approval from the FDA for treatment of patients ≥6 months old with relapsed or refractory pediatric low-grade...
Tovorafenib (Ojemda – Day One), a type II RAF kinase inhibitor, has received accelerated approval from the FDA for treatment of patients ≥6 months old with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion or rearrangement or a BRAF V600 mutation. Tovorafenib is the first systemic treatment to be approved in the US for pediatric low-grade gliomas with BRAF fusions. Accelerated approval of tovorafenib was based on response rates and duration of response.
Med Lett Drugs Ther. 2024 Jun 10;66(1704):e97-8 | Show Full IntroductionHide Full Introduction

In Brief: Dabrafenib (Tafinlar) and Trametinib (Mekinist) for Glioma (online only)

   
The Medical Letter on Drugs and Therapeutics • April 17, 2023;  (Issue 1674)
The oral kinase inhibitors dabrafenib (Tafinlar – GSK) and trametinib (Mekinist – Novartis) have been approved by the FDA for use together for a sixth indication: treatment of low-grade glioma...
The oral kinase inhibitors dabrafenib (Tafinlar – GSK) and trametinib (Mekinist – Novartis) have been approved by the FDA for use together for a sixth indication: treatment of low-grade glioma (LGG) with a BRAF V600E mutation in patients ≥1 years old who require systemic therapy. This combination is the first systemic therapy to be approved in the US for first-line treatment of LGG with a BRAF V600E mutation in pediatric patients. The FDA also approved new oral formulations of both drugs for patients who are unable to swallow dabrafenib capsules or trametinib tablets.
Med Lett Drugs Ther. 2023 Apr 17;65(1674):e75-6 | Show Full IntroductionHide Full Introduction